YieldMax MRNA Option Income Strategy ETF

YieldMax MRNA Option Income Strategy ETF is offered by YieldMax, a leading player in the field of passive investments.

The total expense ratio of YieldMax MRNA Option Income Strategy ETF is 1.27%, which means that investors pay 127 USD per 10,000 USD in investment capital annually.

The ETF is listed in USD.

European investors may incur additional costs for currency exchange and transaction fees.

No, YieldMax MRNA Option Income Strategy ETF does not comply with the EU UCITS investor protection directives.

The current average trading volume of YieldMax MRNA Option Income Strategy ETF is 137,531.8.

YieldMax MRNA Option Income Strategy ETF is domiciled in US.

The fund was launched on 10/23/2023.

The YieldMax MRNA Option Income Strategy ETF mainly invests in Healthcare companies.

The NAV of YieldMax MRNA Option Income Strategy ETF amounts to 19.49 M USD.

Investments can be made through brokers or financial institutions that provide access to trading ETFs.

The ETF is traded on the stock exchange, similar to stocks.

Yes, the ETF can be held in a regular securities account.

The ETF is suitable for both short-term and long-term investment strategies, depending on the investor's goals.

The ETF is valued on a daily stock exchange basis.

Information on dividends should be requested from the provider's website or your broker.

The risks include market fluctuations, currency risks, and the risk associated with smaller companies.

The ETF is obligated to report regularly and transparently on its investments.

The performance can be viewed on Eulerpool or directly on the provider's website.

Further information can be found on the official website of the provider.